Sponsored byOpenSourceMed

Association with Symptoms

Summaries of cohort studies examining whether persistent spike protein detection correlates with multi-system symptoms — including findings of association in subsets and null results in others.

Swank & Walt — Circulating spike associated with Long COVID after infection

Evidence: Medium

Plasma from people with post-acute sequelae of COVID-19 (PASC) and from people recovering from COVID-19 without sequelae was tested with an ultra-sensitive Simoa assay. SARS-CoV-2 spike was detected predominantly in PASC patients, up to 12 months after diagnosis. This is an infection study; it did not examine vaccination.

Limitations

  • Observational design; no randomized controls
  • Small cohort from a single research network
  • Assay sensitivity limits detection in low-level carriers
  • Association does not establish that spike causes symptoms

Yale LISTEN — Circulating spike in post-vaccination syndrome

Evidence: Low

A cross-sectional preprint of 42 people with post-vaccination syndrome (PVS) and 22 healthy controls found higher circulating spike protein in the PVS group, along with differences in T-cell profiles and more frequent signs of Epstein-Barr virus reactivation.

Limitations

  • Preprint; not yet peer reviewed
  • Small, self-selected symptomatic cohort
  • Unrecognised infection cannot be fully excluded as the spike source
  • Cross-sectional; cannot establish causality

Rong et al. — Spike at the skull-meninges-brain axis after infection

Evidence: Low

Using optical tissue clearing and imaging, researchers found SARS-CoV-2 spike protein accumulated in the skull marrow, meninges and brain of deceased COVID-19 patients, persisting long after viral clearance. Long COVID patients had raised markers of neurodegeneration in cerebrospinal fluid, and spike injection alone caused neuroinflammation in mice.

Limitations

  • Autopsy findings; persistence duration not quantified
  • Infection-derived spike; not a vaccine study
  • Human-to-symptom link inferred partly from mouse models
  • Needs independent replication

Studies showing no or weak symptom correlation

Evidence: Medium

Several population-based and controlled studies have not found a consistent association between circulating spike detection and symptom burden in general vaccinated populations. Detection rates in asymptomatic individuals and the role of assay false positives/false negatives remain active areas of investigation.

Limitations

  • Heterogeneous symptom definitions across studies
  • Many studies lack ultra-sensitive spike assays
  • Healthy control comparison groups often small

Multi-system symptom patterns in persistent-carrier cohorts

Evidence: Low

In subsets of patients with prolonged spike detection, reports include overlapping cardiovascular, neurological, and autonomic symptoms reminiscent of post-acute infection syndromes. Whether this reflects shared immunological pathways, endothelial dysfunction, or reporting bias is not yet resolved.

Limitations

  • Overlap with long COVID symptom profiles confounds attribution
  • No validated clinical biomarker threshold for treatment decisions
  • Psychosocial and functional factors not fully accounted for

Serum spike persistence not associated with ME/CFS diagnosis

Evidence: Medium

A study measuring serum spike protein in post-COVID patients with predominant fatigue and exertional intolerance — including a subset meeting ME/CFS diagnostic criteria — found no association between spike persistence and ME/CFS status. This is a notable null finding given fatigue is one of the most commonly proposed spike-associated symptoms.

Limitations

  • Single-cohort study; may not generalize to other post-COVID fatigue phenotypes
  • ME/CFS diagnostic criteria are themselves symptom-based and heterogeneous
  • Absence of correlation does not rule out a role for spike in a minority subgroup

Spike protein as one of several biomarkers in long COVID risk stratification

Evidence: Medium

A broader biomarker-based risk assessment approach situates spike protein persistence alongside proinflammatory mediators (cytokines, complement markers) as part of a multi-marker strategy for anticipating postinfection sequelae, rather than treating spike detection as a standalone diagnostic signal.

Limitations

  • Proposed risk-assessment framework, not a validated clinical diagnostic test
  • Relative weighting of spike vs. other biomarkers not firmly established
  • Requires prospective validation across diverse patient populations

Retrospective comparison of spike variants and long COVID biological factors

Evidence: Low

A retrospective cohort study comparing biological factors across SARS-CoV-2 spike protein variants examined associations with long COVID outcomes, contributing variant-stratified evidence to the broader symptom-correlation literature rather than treating spike protein as a single uniform exposure.

Limitations

  • Retrospective design; residual confounding by variant-era clinical practice differences
  • Regional cohort (Thailand); generalizability to other populations unclear
  • Variant classification relied on epidemiological timing rather than individual sequencing in all cases

Narrative review of spike protein in long COVID pathophysiology

Evidence: Low

A 2025 review synthesizes proposed pathophysiological mechanisms linking spike protein (viral or vaccine-derived) to Long COVID symptom clusters, integrating the mechanistic literature (endothelial, neurologic, immune) with the clinical symptom-correlation studies summarized on this page.

Limitations

  • Narrative rather than systematic review methodology
  • Synthesizes mechanistic plausibility rather than new primary clinical data
  • Causal role of spike persistence in symptom generation remains unproven

Key takeaway

The relationship between spike persistence and symptoms remains contested. Some symptomatic cohorts show higher detection rates, but population-level studies often fail to replicate a strong correlation. Causality has not been established in any prospective trial.